Recent Comments

Comment RSS

Acadesine News and Research RSS Feed - Acadesine News and Research

Acadesine is a 5-aminoimidazole-4-carboxamide (AICA) riboside, a purine nucleoside analog, and a nucleotide biosynthesis precursor with B cell pro-apoptotic activity.

Ligand Pharmaceuticals and Metabasis Therapeutics enter into definitive merger agreement

27. October 2009 08:30
Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc. (NASDAQ: MBRX) announced today they have entered into a definitive merger agreement under which Ligand will acquire all of the outstanding shares of Metabasis. [More]

Ligand Pharmaceuticals, Metabasis Therapeutics enter into merger agreement

27. October 2009 08:28
Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc. (NASDAQ: MBRX) announced today they have entered into a definitive merger agreement under which Ligand will acquire all of the outstanding shares of Metabasis. [More]

Schering-Plough starts patient enrollment in phase 3 trial for Acadesine

12. May 2009 07:56
Schering-Plough Corporation today announced the start of patient enrollment in RED-CABG, the Phase 3 Trial for acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA). Acadesine was licensed from PeriCor Therapeutics, Inc., a privately held specialty biopharmaceutical company. [More]

Schering-Plough announces licensing of Acadesine

20. July 2007 12:23
Schering-Plough Corporation has announced the worldwide licensing of acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA), from PeriCor Therapeutics, Inc., a privately held, specialty biopharmaceutical company. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.